New hope for babies with severe epilepsy: drug trial targets seizures in toddlers

NCT ID NCT06118255

Ongoing Disease control Sponsor: UCB BIOSCIENCES, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests a medicine called fenfluramine in 25 infants aged 1 to 2 years who have Dravet syndrome, a severe form of epilepsy. The goal is to see if the drug is safe and can reduce seizures. Researchers will closely monitor heart health and growth, since the medicine has known risks. This is a phase 3 trial, meaning it is one of the final steps before possible approval for this age group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ep0213 103

Seattle, Washington, 98105, United States
Ep0213 105

Memphis, Tennessee, 38103-2800, United States
Ep0213 107

Dallas, Texas, 75207, United States
Ep0213 201

Roma, Italy
Ep0213 202

Florence, Italy
Ep0213 203

Genova, Italy
Ep0213 204

Roma, Italy
Ep0213 303

Bielefeld, Germany
Ep0213 401

London, United Kingdom
Ep0213 403

Glasgow, United Kingdom
Ep0213 501

Edegem, Belgium
Ep0213 502

Brussels, Belgium

Conditions

Explore the condition pages connected to this study.

DRAVET SYNDROME